Keyphrases
Secukinumab
100%
Axial Spondyloarthritis (AxSpA)
95%
Psoriatic Arthritis
66%
Patient-reported Outcomes
41%
Arthritis Patients
40%
Remission
38%
Targeted Synthetic Disease-modifying Antirheumatic Drugs
37%
Routine Care
37%
Daily Clinical Practice
33%
Non-radiographic Axial Spondyloarthritis
33%
Treatment Outcome
33%
Real Patients
33%
Retention Rate
29%
Remission Rate
23%
Low Disease Activity
18%
Drug Retention
16%
Nave
14%
Activity Rate
14%
Inactive Disease
8%
Ankylosing Spondylitis Disease Activity Score (ASDAS)
8%
Adjusted Analysis
7%
Numeric Rating Scale
7%
Patient Global Assessment
7%
Health Assessment Questionnaire
7%
Cox Regression Analysis
7%
Logistic Regression Analysis
7%
European Registries
7%
Kaplan-Meier Plot
7%
Pharmacology, Toxicology and Pharmaceutical Science
Secukinumab
100%
Spondylarthritis
100%
Psoriatic Arthritis
66%
Remission
51%
Disease Modifying Antirheumatic Drug
35%
Observational Study
33%
Disease Activity
24%
Ankylosing Spondylitis
6%
Medicine and Dentistry
Observational Study
33%
Secukinumab
33%
Spondylarthritis
33%
Drug Retention
8%
